

OPEN ACCESS

APPROVED BY

Frontiers Editorial Office, Frontiers Media SA, Switzerland

*CORRESPONDENCE Richard A. Slayden,

☑ richard.slayden@colostate.edu

[†]These authors have contributed equally to this work

RECEIVED 27 October 2025 ACCEPTED 28 October 2025 PUBLISHED 18 November 2025

CITATION

Cummings JE, Woolhiser LK, Guglielmi V, Wernsman M, Romano A, Pauly S, Belisle JT, Walter ND, Robertson GT and Slayden RA (2025) Correction: Evaluating the efficacy of HRZE-based regimens in a high-burden murine model: a back-translational assessment of rifamycins and moxifloxacin substitutions in tuberculosis treatment. *Front. Pharmacol.* 16:1733648.

Front. Pharmacol. 16:1733648. doi: 10.3389/fphar.2025.1733648

COPYRIGHT

© 2025 Cummings, Woolhiser, Guglielmi, Wernsman, Romano, Pauly, Belisle, Walter, Robertson and Slayden. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY).

The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Correction: Evaluating the efficacy of HRZE-based regimens in a high-burden murine model: a back-translational assessment of rifamycins and moxifloxacin substitutions in tuberculosis treatment

Jason E. Cummings^{1†}, Lisa K. Woolhiser^{1†}, Vincent Guglielmi¹, Machenzie Wernsman¹, Ashley Romano¹, Samantha Pauly^{2,3}, John T. Belisle¹, Nicholas D. Walter^{2,3,4}, Gregory T. Robertson^{1,2} and Richard A. Slayden^{1*}

¹Mycobacteria Research Laboratories, Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, United States, ²Consortium for Applied Microbial Metrics, Aurora, CO, United States, ³Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, United States, ⁴Rocky Mountain Regional VA Medical Center, Aurora, CO, United States

KEYWORDS

high-burden aerosol BALB/c model, high burden, tuberculosis, mycobacteria, drug discovery

A Correction on

Evaluating the efficacy of HRZE-based regimens in a high-burden murine model: a back-translational assessment of rifamycins and moxifloxacin substitutions in tuberculosis treatment

by Cummings JE, Woolhiser LK, Guglielmi V, Wernsman M, Romano A, Pauly S, Belisle JT, Walter ND, Robertson GT and Slayden RA (2025). Front. Pharmacol. 16:1667592. doi: 10.3389/fphar. 2025.1667592

There was a mistake in Figure 1 as published. **Figure S1** was published in place of the true Figure 1. The corrected Figure 1 appears below.

Supplemental material **Figure S1** was omitted. The file has now been published. The original article has been updated.

Cummings et al. 10.3389/fphar.2025.1733648




FIGURE 1
Study design for evaluating treatment duration-dependent responses to standard HRZE therapy in a murine model of Mycobacterium tuberculosis infection. Mice were aerosol-infected with M. tuberculosis on Day–11 and one group was sacrificed at Day 1 post-infection to establish baseline lung bacterial burden. All remaining animals remained untreated until Day 0, at which point treatment (Tx) was initiated. Groups received treatment for 2, 4, or 8 weeks, with corresponding sacrifices on Days 12, 26, and 54 to assess treatment efficacy. Endpoints included colony-forming unit (CFU) enumeration and determination of RS Ratio. Day 54 mice were also evaluated for histopathological changes and PK analysis. A parallel untreated control group was maintained through the full 8-week period.

intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Generative AI statement

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial